are specific to the drug e.g. recovery from paralysis due to a neuroactive drug 23 requires neurotransmitter pathways whereas recovery from a metabolic 24 inhibitor requires metabolic changes. Finally, we also find that acute 25 responses can vary greatly across development and that there is extensive and 26 complex natural variation in acute responses. In summary, acute responses 27 are sensitive probes of the ability of biological networks to respond to drug 28 treatment and these responses can reveal the action of unexplored pathways. 29
30

Author Summary
31
Drugs are powerful tools that let us switch on or off key pathways in whole animals and 32 watch the effects. Here we set up a simple assay to measure how drugs affect the 33 movement of the simple nematode C.elegans -crucially, we look how those responsesIntroduction 46 Drugs are extremely powerful research tools. Addition of a drug can turn on or off aspecific target protein and the effect on the organism can be followed over time. In 48 model organisms, a well-characterized drug response can form the basis for genetic 49 screens to identify the drug target and to find genes that modulate the effect of the 50 drug. In C.elegans, for example, genetic screens for mutants with altered drug 51 responses were key to finding the targets of several major anthelmintics (1-4) as 52 well as to identifying core components of conserved neuronal signaling pathways 53 (5,1,6,7). 54
Many genetic screens for C.elegans mutants with altered drug responses have 55 screened for mutants that escape the effects of chronic exposure to drugs. In these 56 screens, populations of mutant worms are typically exposed to drugs for several 57 days (8-13). However, many drugs act very rapidly on worms yet currently 58 genes that affect the acute responses -are they the same or different genes as 64 those that affect long-term drug effects? 65
Our goal in this study was to examine acute drug responses in C.elegans and address 66 at least some of these questions. We developed an image-based method that 67 accurately measures worm movement at high throughput. This allows us to gather 68 8 affects the dose-response relationship of aldicarb: in the presence of 600 M 137 mecamylamine, the EC50 of aldicarb shifts from 0.76 mM to 1.6 mM, with a slight 138 decrease in maximal response (Fig 2C) . The effects of Ald on worm movement that 139 we measure in our assay are thus specific to the action of elevated ACh on nAChRs 140
and not some non-specific effect on movement. 141 We note that while we focus here on the use of this assay to measure the effects of 142 drugs on worm movement, it can also be used to measure the effect of genetic 143 perturbations on movement directly. To illustrate this, we used RNA-mediated 144 interference (RNAi) to knock down 7 genes that are known to be required for wild-145 type movement and measured movement after RNAi. We found robust RNAi 146 phenotypes for all 7 genes ( Fig 2D) showing that our movement assay is applicable 147 to both genetic and drug based screens. Thus, we expect our method to be 148 applicable in a range of pharmacological, genetic, and RNAi experiments. 149
We have thus developed a simple method that allows us to measure the acute effects 150 of drug treatments on worm movement at high throughput. We showed that our 151 assay recapitulates the known effects of the well-characterised neuroactive drug Ald 152 and that this is indeed due to its known mode of action through the activation of 153 specific receptors. Crucially, our assay allows us to measure both dose responses 154 and time-resolved responses to drugs. In the rest of this paper we demonstrate that 155 time-resolved profiles of drug responses can yield new insights into C. elegans 156 biology.
time periods of minutes to hours. We wanted first to use this to explore acute 160 responses in general -what do these look like for a variety of drugs and 161 treatments? We exposed C.elegans L1 larvae to a wide range of different compounds 162 and treatments including compounds that inhibit core essential machineries such as 163 the electron transport chain (inhibition by potassium cyanide, KCN, shown in Fig  164   3A ) or the ribosome (effect of cycloheximide in Fig 3B) , environmental stresses such 165 as high salt conditions (NaCl shown in Fig 3C) , known nematicides (abamectin 166 shown in Fig 3D) , as well as compounds that affect movement via altered 167 neurotransmission (e.g. aldicarb Fig 2A) . In each case, worms were treated and their 168 movement examined over a time course of 3 hours -at least 3 biological replicates 169
were done for each treatment. 170
In addition to this panel of characterized compounds, we also tested a range of novel 171 compounds that had been identified as affecting worm growth in chronic exposure, 172 population growth assays (13). We examined the effects of 170 of these on the 173 movement of L1 larvae and find that many (53/170) also have acute effects on 174 worm movement. Crucially, an unexpectedly high proportion (31 of 53 with acute 175 effects; 58%) of drugs tested show complex time-resolved responses illustrated in 176 Having looked at acute responses to across a range of different treatments, we found 178 complex acute responses across every type of compound, including neuro-activecompounds, environmental stresses, and toxins that target essential genes. These 180 responses can be very complex -for example, the novel compound shown in Fig 3G  181 has two distinct phases of recovery and several structurally related compounds 182 have similarly complex responses (data not shown). We note that every one of these 183 complex drug responses can be the basis either for a genetic screen for mutants 184 with altered responses or for drug screens for compounds that modulate the 185 response. This complexity of many acute drug responses underlines the need to be 186 able to measure time-resolved acute effects of drugs on movement. 187
The complex effects of many compounds over time suggest that the worms are 188 responding to many drug treatments in some way -for example, several drugs 189 cause an initial rapid paralysis followed by a recovery phase where the worms begin behave completely differently-Ald induces rapid paralysis of L1 worms but this is 199 followed by a more gradual recovery (Fig 4A; S2) . To further examine the Ald 200
response across development, we tested all developmental stages and found the 201 response is qualitatively very different across development (Fig 4A) Nic show a rapid initial paralysis followed by a recovery of movement (Fig 4B) . 215 While these two responses have superficial similarities, there is a crucial difference 216 in the recovery phase. For Nic, while L1 worms recover from the reduction of 217 movement caused by low doses of Nic, increasing concentrations of Nic result in 218 greater paralysis and less recovery until at high Nic doses there is no appreciable 219 recovery (Fig 4D) . For Ald, we see the precise opposite -there is no recovery at 220 low doses of Ald, but recovery increases with increasing Ald (Fig 4C) . This suggests 221 that the recovery from Ald and Nic-induced paralysis is fundamentally different and 222 that Ald is somehow driving recovery since the more Ald we add, the stronger the 223 recovery. How could Ald be acting and how could this be different to Nic? To test whether recovery from Ald-induced paralysis might be due to the activation 235 of mAChRs, we examined whether a mAChR antagonist, atropine (Atr), could block 236 the recovery phase of the Ald response. This is indeed the case (Fig 5A) suggesting 237 that recovery is the result of an activation of mAChR signaling following increased 238 ACh levels after Ald treatment. The C. elegans genome encodes three muscarinic 239 acetylcholine receptors, GAR-1, GAR-2 and GAR-3 (27-29) -we obtained deletion 240 mutants for each of these receptors and tested whether the effect Ald was altered in 241 these mutant strains. The Ald response is clearly different in the gar-3(gk305) 242 mutant strain: while the paralysis phase appears very similar to wild-type, the 243 recovery phase is strongly suppressed in the gar-3(gk305) mutant, although not 244 completely abolished (Fig 5B) . We note that mutations in gar-1 and gar-2 also have 245 effects on recovery but these are much weaker and we suggest that gar-3 is the key 246 mAChR that drives recovery from nAChR stimulation in L1 animals. 247
We thus propose that Ald causes a complex acute response in L1 worms because the 248 increased ACh levels have effects on two separate neurosignalling pathways. The 249 first phase of the acute response is a rapid reduction in movement due to activation 250 of nAChRs. The second phase is a slower recovery due to activation of mAChRs 251 which somehow relieve the nAChR-driven paralysis. To further test this, we 252 examined whether we can drive recovery from Nic-induced paralysis with agonists 253 of mAChRs. Nic can only stimulate nAChRs and has no activity on mAChRs (30). 254 Consistent with our model, we find that we can induce recovery from Nic-induced 255 paralysis either by adding Ald (Fig 5C) or the mAChR agonists, Oxotremorine M 256 (OxoM) or Arecoline (Are) (Fig 5D; supplementary S3 ). To confirm that the same 257 mAChR requirement apply to OxoM-induced recovery as in Ald responses, we tested 258 the ability of each gar mutant to recover from Nic-induced paralysis in the presence 259 of OxoM (Fig 5E) . We found that gar-3 is indeed the primary mAChR driving OxoM-260 induced recovery. Our data suggest that mAChR signalling can drive recovery from 261 paralysis induced by sustained nAChR activation. Finally, we examined whether 262 changes in mAChR signalling might underlie the difference in the ability of L1 and 263 adults to recover from Ald paralysis. We find that stimulation of mAChR signalling 264 by OxoM in adults cannot override the paralysis response ( Fig 5F) We immediately noticed that the dose response at early time points were very 286 unusual -while intermediate doses of KCN caused almost complete paralysis 287 movement, high doses appeared to have little effect (Fig 7A) . This was most 288 pronounced in DRCs between 15-30minutes -by ~60 minutes the DRCs appeared 289 much more normal, with increased effects being seen with increased dose. 290
How can the effect of low concentrations of KCN be greater than the effect of high 291 concentrations? We reasoned that this may be due to rewiring of metabolic 292 pathways -worms might respond to high KCN concentrations by rapidly switching 293 to use alternative metabolic pathways for generating ATP. An obvious candidate for 294 such a pathway was anaerobic glycolysis which is the major pathway for ATP 295 generation in anaerobic conditions in many animals -indeed we found that 296 addition of 2-deoxy-D-glucose, an inhibitor of phosphoglucose isomerase, a critical 297 enzyme in anaerobic glycolysis, caused a profound change in KCN DRCs. Worms can 298 no longer continue moving in high doses of KCN when 2DG is also present -instead 299 we find that increased concentrations of KCN result in decreased movement at all 300 time points (Fig 7A) . This suggests that the unusual DRCs seen for KCN alone were 301 due to a shift to utilization of anaerobic glycolysis at early timepoints in high KCN 302 (Fig 7B) . 303
This underscores the importance of measuring drug responses across time -if we 304 had only measured KCN DRCs at 80 minutes, they would have looked completely 305 unremarkable. It also confirms that the way that worms respond to acute drug 306 treatment is highly specific to the drug itself -while the aldicarb response involves 307 crosstalk between nAChRs and mAChRs, the KCN response involves metabolic 308 switches. The rapid responses of worms to compounds thus do not appear to be 309 generic stress or xenobiotic responses but are specific responses to the specific drug 310 effects. They reveal how the organism can rewire and adapt to sudden inhibition of 311 a key pathway. 312 313 Natural variation in acute drug response is very complex 314 Drug responses are known to vary within natural populations. In C.elegans, natural 315 variation in drug responses has been seen for several drugs including abamectin 316 and etoposide (32,33). In a previous study we compared the effects of KCN on two 317 natural isolates, the N2 and CB4856 isolate (34). These differ by around 318 1SNP/800bp (35), a similar degree of variation as that between two human 319 genomes. In our previous study we simply examined one time point (90 minutes 320 after drug treatment) and only looked at a single larval stage, the L1 stage -we 321 wanted to expand this analysis to compare the effects of KCN on N2 and CB4856 322 across development. We decided to examine how a range of concentrations of KCN 323 affect movement of all 4 larval stages of either N2 or CB4856 and in each case to 324 examine how this response evolves over 3hr (Fig 8) . 325
The results are complex and striking. In keeping with our previous study (34), we 326 find that N2 are more affected by KCN at the L1 stage. However, we find the exact 327 reverse at the L4 stage -CB4856 are substantially more sensitive here. At the L3 328 stage, the picture is even more complex -while KCN appears to affect CB4856 329 more rapidly (CB4856 L3 animals are more severely affected at early timepoints), 330 the same dose of KCN has a more severe effect on N2 later timepoints. example, we found that L1 larvae recover readily from Aldicarb-induced paralysis 375 but adults cannot recover. The recovery of L1s from Ald-induced paralysis is highly 376 dose-dependent -L1s do not recover at 2mM Ald but recover readily at the higherconcentration of 6mM (Fig 4A) . This kind of complexity means one cannot simply 378 say 'C.elegans can recover from Ald paralysis' or 'C.elegans cannot recover from Ald 379 paralysis'. We see a similar complexity when we look at natural variation in acute 380 responses. We compared the sensitivity to KCN of two natural isolates of C.elegans, 381 N2 and CB4856 and find a complex picture -while N2 is more sensitive at the L1 382 stage, CB4856 is more sensitive at the L4 stage. Again, we cannot make a blanket 383 statement of 'N2 is more sensitive than CB4856' -dose, time point, and 384 developmental stage drive major differences in the drug responses and these factors 385 are often neglected. For example a GWAS to identify QTLs that affect 'drug 386 sensitivity' would likely find different variants depending on drug dose and 387 developmental stage assayed. Crucially, this means that to really understand acute 388 responses, we need to measure them over a range of doses and for each 389 
Materials and Methods
418
Worm Maintenance and Strains
419
All worm stocks were maintained at 20ºC on NGM agar plates seeded with E.coli 420 strain OP50 as described elsewhere (41). In addition to the classical laboratory 421 strain N2, we describe work using strains unc-38 (e264), lev-8 (x15), lev-1 (e211), buffer apart from the screen for compounds that modify the response to aldicarb, 464 which were assembled in modified NGM, which we found to cause fewer problems 465 of drug precipitation. After assembling the assay, plates were sealed with 466 transparent, self-adhesive films before imaging. The point at which worms and 467 drugs were combined marked the start of the assay. 468 treated and mock-treated worms were filtered to purify L1 worms and washed in 471 two buffer changes of M9. Purified L1 samples were diluted to approximately 1.2 472 worms per microlitre and 100 µl samples were transferred to microtitre plates for 473 use in mobility assays. 474
Image acquisition, analysis and calculation of fractional mobility score: Our image analysis pipeline was prepared with the python programming language 494 using the scikit-image library (44). All images were first processed with a Gaussian 495 blur to reduce noise levels. Further image analysis consisted of two sets of processes 496 to find moving and non-background, non-moving parts of the images. 497
To identify non-background, non-moving pixels, images were processed using a 498
Sobel filter, which effectively produces the first derivative of the image, thus edges 499 are highlighted and sharper edges appear brighter than shallow edges. An adaptive 500 threshold was applied to the Sobel images to remove the background and yield a 501 binary image. These binary images contained the outlines of the well and any 502 objects, such as worms, within the well. Binary images were further processed with 503 two iterations of binary closing to fill the pixels between sufficiently close edges. 504
This process was hand-tuned to fill in the area occupied by worms but minimize 505 overfilling into the areas between worms. A circular binary mask was applied to 506 remove the edges of the wells from each binary image and one of these images was 507 designated as a reference image for each well ( Figure 1A, Image B) . 508 Pixels associated with movement were identified by calculating the absolute 509 difference of the two consecutive images of a well ( Figure 1A, Image A) . A threshold 510 was applied to the difference image to create a binary image ( Figure 1A, Image B) . 511
This binary image contained the moving pixels from both parent images, showingdouble the number of movement-associated pixels. To correct for this, we multiplied 513 the binary difference image by the reference image described above revealing only 514 the non-background, movement associated pixels from a single frame ( Figure 1A , 515 Image C). Finally to identify pixels that did not move between wells, the reference 516 image was multiplied by the complement of Image C ( Figure 1A, Image D) . 517
A fractional mobility score was calculated as the ratio of movement-associated 518 pixels to total non-background pixels. This process is contained in the Python script 519 quantify_movement.py. A second Python script, quantify_movement_adult.py, was 520 used to analyse images of adult worms. This script contains an additional step to 521 mask out objects below a certain number of pixels in size, to remove eggs from the 522 analysis, since some chemicals stimulate egg-laying. 
